Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
squalamine lactate + ranibizumab
- Development stage
- Phase 3
- Lead developer
- Ohr Pharmaceutical
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Ophthalmic, Intravitreal
01
Overview
Combination of **squalamine lactate**, a small molecule angiogenesis inhibitor formulated for topical ophthalmic use, and **ranibizumab**, a recombinant, humanized anti-VEGF monoclonal antibody fragment indicated for intravitreal injection. Squalamine lactate exerts its effect through intracellular inhibition of multiple angiogenic factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF), via displacement of calmodulin from endothelial cells, thus inhibiting neovascularization. Ranibizumab binds extracellular VEGF-A, preventing receptor activation and downstream angiogenic signaling. The combination aims to enhance visual outcomes in neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO), seeking additive or synergistic inhibition of angiogenesis compared to monotherapy[1][2][3][4][5][6].
- Brand names
- Lucentis (for ranibizumab component)OHR-102 (for squalamine lactate ophthalmic solution)
- Other names
- squalamine lactate ophthalmic solution 0.2% + ranibizumab
02
Targets
CaM (Calmodulin)VEGFA (Vascular endothelial growth factor A)FGF2PDGF (Platelet-derived Growth Factor family)
Beyond the preview
Go deeper on squalamine lactate + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on squalamine lactate + ranibizumab.